Literature DB >> 28326594

Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer.

Liana P Webber1,2,3, Vivian P Wagner1,2, Marina Curra1,2, Pablo A Vargas4, Luise Meurer1,5, Vinícius C Carrard2, Cristiane H Squarize3, Rogério M Castilho3, Manoela D Martins1,2.   

Abstract

AIMS: Epigenetics refers to changes in cell characteristics that occur independently of modifications to the DNA sequence. Oral carcinogenesis is influenced by modifications in epigenetic mechanisms, including changes in histones, which are proteins that support chromatin remodelling for the dynamic regulation of gene expression and silencing. The dysregulation of histone acetylation can lead to the uncontrolled activity of different genes, thereby triggering events associated with malignant transformation. The aim of this study was to analyse the expression of acetyl-histone H3 at lys9 (H3K9ac) in oral leucoplakia (OL) and oral squamous cell carcinoma (OSCC) in addition to its association with cell proliferation, epithelial-mesenchymal transition (EMT) and clinical-pathological findings. METHODS AND
RESULTS: Samples of normal oral mucosa (NOM), OL and OSCC were submitted to immunohistochemical analysis using anti-H3K9ac, Ki67 and vimentin. Slides were submitted to quantitative analysis regarding the percentage of positive cells. OSCC presented less expression of H3K9ac in comparison to OL (P < 0.01), whereas Ki67 and vimentin levels increased from OL to OSCC (P < 0.001 and P = 0.03, respectively). OSCC patients with poor prognosis had less H3K9ac expression (P = 0.04). The Kaplan-Meier cumulative survival curves also revealed lower survival rates in patients with less H3K9ac expression (P < 0.01).
CONCLUSIONS: The present findings suggest that changes in H3K9ac occur during the process of oral carcinogenesis along with an increase in cell proliferation and EMT. The results demonstrate that H3K9ac may be a useful novel prognostic marker for OSCC.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ki67; epigenetic; epithelial-mesenchymal transition; histone; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28326594     DOI: 10.1111/his.13218

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.

Authors:  Liana P Webber; Veronica Q Yujra; Pablo A Vargas; Manoela D Martins; Cristiane H Squarize; Rogerio M Castilho
Journal:  Cancer Lett       Date:  2019-06-29       Impact factor: 8.679

2.  Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells.

Authors:  Luan César Silva; Gabriell Bonifácio Borgato; Vivian Petersen Wagner; Manoela Domingues Martins; Guilherme Zweig Rocha; Márcio Ajudarte Lopes; Alan Roger Santos-Silva; Gilberto de Castro Júnior; Luiz Paulo Kowalski; Jacques E Nor; Cristiane H Squarize; Rogerio Moraes Castilho; Pablo Agustin Vargas
Journal:  J Oral Pathol Med       Date:  2021-10-27       Impact factor: 3.539

Review 3.  Epigenetic alterations in ameloblastomas: A literature review.

Authors:  Erison-Santana Santos; Carla-Isabelly Rodrigues-Fernandes; Joab-Cabral Cabral; Felipe-Paiva Fonseca; Adriana-Franco-Paes Leme
Journal:  J Clin Exp Dent       Date:  2021-03-01

4.  Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling.

Authors:  Muhammad Shahid; Min Young Lee; Honit Piplani; Allen M Andres; Bo Zhou; Austin Yeon; Minjung Kim; Hyung L Kim; Jayoung Kim
Journal:  Cell Cycle       Date:  2018-12-17       Impact factor: 5.173

5.  GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma.

Authors:  Mengyuan Li; Hongwei Jiang; Shengjiang Chen; Yujin Ma
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 6.  Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.

Authors:  Rogerio M Castilho; Cristiane H Squarize; Luciana O Almeida
Journal:  Int J Mol Sci       Date:  2017-07-12       Impact factor: 5.923

Review 7.  H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.

Authors:  Marta Hałasa; Anna Wawruszak; Alicja Przybyszewska; Anna Jaruga; Małgorzata Guz; Joanna Kałafut; Andrzej Stepulak; Marek Cybulski
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

Review 8.  Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics.

Authors:  Ana Capote-Moreno; Eva Ramos; Javier Egea; Francisco López-Muñoz; Emilio Gil-Martín; Alejandro Romero
Journal:  Cancers (Basel)       Date:  2019-11-02       Impact factor: 6.639

9.  Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.

Authors:  Vivian P Wagner; Manoela D Martins; Marco A T Martins; Luciana O Almeida; Kristy A Warner; Jacques E Nör; Cristiane H Squarize; Rogerio M Castilho
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

10.  [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors].

Authors:  Pan Wang; Honglin Zhao; Fan Ren; Qingchun Zhao; Ruifeng Shi; Xingyu Liu; Jinghao Liu; Yongwen Li; Ying Li; Hongyu Liu; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.